Beruflich Dokumente
Kultur Dokumente
Cardium is focused on the acquisition and strategic development of product opportunities and businesses having the potential to address significant unmet medical needs, and definable pathways to commercialization, synergistic sale, partnering and other monetizations following the achievement of corresponding development objectives and economic valuation inflection points.
Investment Highlights
Capital-efficient business strategy focused on finding diamonds in the rough and leveraging research and development investments by big pharma, venture and institutional investors Strategy intended to provide a diversified and more balanced portfolio of risk/return opportunities Generx Global Cardiovascular Platform: International cost-efficient Phase 3 / Registration Study now cleared for initiation Study Design: 100 patients with SPECT imaging efficacy endpoint Initial medical focus: Patients in Russia with advanced coronary artery disease who have limited access to costly and rationalized bypass surgery and angioplasty / stent procedures (Russian CVD death rates 5X greater than U.S.; average life expectancy for males 57 years) Excellagen Wound Care Management Platform: Initial product has pending FDA 510(k) submission for marketing and sales clearance Devro Medical currently manufacturing commercial supplies for market launch Initial focus on diabetic foot ulcers Other product line extensions currently under development Next focus: Pressure Ulcers MedPodium In-House Brand Platform: Portfolio of premium, science-based, easy-to-use conditionspecific nutraceuticals designed to promote personal health and well being for today's active, informed and professional lifestyles Seeking revenue-based strategic acquisitions in the nutraceutical space Acquisition Search: Challenging economic environment continues to generate a steady stream of deal flow CXM remains highly selective focused primarily on late-stage clinical development opportunities and revenue-based businesses Key Investor Metrics: No outstanding debt, substantial trading liquidity, continuing news flow expected Current capital structure provides for significant economic upside potential as CXM executes business strategy Capital-efficient ATM Shelf Registration in place
Portfolio Status
Company Acquisition Current Key Product Generx [Ad5FGF-4] Phase 3 Registration Study for International Markets
Strategic Sale to
August 2006
Tissue Repair Company DNA-Activated Matrices for Wound & Orthopedic Repair
Generx [Ad5-FGF4]
Catheter-Based Intracoronary Delivery Angiogenic Microvascular Circulation
One-Time Treatment
DNA-Based Delivery
Angiogenic Response
AGENT-2 - Representative Generx-treated patient: 77% improvement in cardiac perfusion at 8 weeks equivalent to bypass surgery and PCI (angioplasty/stenting) at one year.
Parameter
Number of Patients Age Stress defect extent (%) Reduction of reversible defect (%)
206
6611
6810
579
598
1811
1610
208
209
-512
-0.87
-0.86
-46
10
Beneficial Effects of Collateral Vessels 10-Year Follow-up in Patients with Heart Disease
% CARDIAC DEATHS: Cumulative Survival Rate 10 year follow-up (n = 845) High Flow: 5 (2%) Deaths Low Flow: 37 (6%) Deaths (low collateral flow) (high collateral flow) 67% Cardiac Deaths
11
1999
AGENT-1
U.S.
Class 2 3 Angina >9% Reversible Reperfusion Defect Class 2 4 Angina Class 2 4 Angina
2001
AGENT-2
North America
SPECT Imaging
52
2004
AGENT-3
Exercise Treadmill Time Exercise Treadmill Time Exercise Treadmill Time (Time to ST Segment Depression SPECT Imaging
300
2004
AGENT-4
Phase 2b/3
252
2008
2011 Cardium Therapeutics, Inc.
AWARE
U.S.
Phase 3
Class 3 4 Angina
2011
ASPIRE
Russian Federation
100
TOTAL
783
12
Cardiovascular Death Rates per 100,000 (Ages 35-74) Males2 Cardiovascular Death Rates per 100,000 (Ages 35-74) Females2
1R 2American
13
Target Revenue per Dose Level I $2,000 / dose $100 Million Level II $3,000 / dose $150 Million Level III $4,000 / dose $200 Million
50,000 doses
100,000 doses
$200 Million
$300 Million
$400 Million
150,000 doses
2011 Cardium Therapeutics, Inc.
$300 Million
$450 Million
$600 Million
200,000 doses
$400 Million
$600 Million
$800 Million
14
15
16
Pre-Formulated Plug-N-Play Pre-filled Single Use Sterile Syringe Refrigerated Storage Required
17
Debride
Treat
Bandage
Offload
18
Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers Blume P, et al. Wound Repair Regen. 2011 May-Jun;19(3):302-8.
19
Annual
1.3 Million 14 per patient 7 per patient
9.1 Million
$5 Million $10 Million $20 Million $35 Million $50 Million $70 Million $80 Million
Diabetes Association.
Department of Health and Human Services: Agency for Healthcare Research and Quality. $95.00/per Excellagen Treatment.
3 Assumes
20
MedPodium is a portfolio of premium, science-based, easy-to-use condition-specific nutraceuticals, metabolics, aesthetics, and other products designed to promote personal health and well being based on natural formulations
2011 Cardium Therapeutics, Inc.
for today's active, informed and professional lifestyles. MedPodium's products address healthy lifestyle interests that are increasingly important in our technology-based society, including millennials (young adults aged 20 to 35) who are leading the information revolution. The MedPodium brand will focus on sealed capsules, quality, easy to use pills, as well as novel, fast-acting drops and sprays, and transdermal delivery system.
21
22
Wound Healing
Periodontal
Cardiovascular
Orthopedic
23
Disease Focus
Medical Indication
Mechanism of Action
Generx (Cardionovo)
Ad5-FGF4
Heart Disease
Myocardial Ischemia
Angiogenesis
Excellerate
Ad5-PDGFB
Wound Healing
Tissue Regeneration
Osteorate
Ad5-PDGFB AdBMP-4
Orthopedics
Periorate
2011 Cardium Therapeutics, Inc.
Ad5-PDGFB
Dental
Corgentin
Ad5-IGF1
Heart Attack
Myocardial Infarction
24
25